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ABSTRACT
Introduction: In the Americas, mucosal leishmaniasis is primarily associated with infection by Leishmania (Viannia) 
braziliensis. However, Leishmania (Viannia) guyanensis is another important cause of this disease in the Brazilian Amazon. 
In this study, we aimed at detecting Leishmania deoxyribonucleic acid (DNA) within parafﬁ n-embedded fragments of mucosal 
tissues, and characterizing the infecting parasite species. Methods: We evaluated samples collected from 114 patients treated at 
a reference center in the Brazilian Amazon by polymerase chain reaction (PCR) and restriction fragment length polymorphism 
(RFLP) analyses. Results: Direct examination of biopsy imprints detected parasites in 10 of the 114 samples, while evaluation 
of hematoxylin and eosin-stained slides detected amastigotes in an additional 17 samples. Meanwhile, 31/114 samples (27.2%) 
were positive for Leishmania spp. kinetoplast deoxyribonucleic acid (kDNA) by PCR analysis. Of these, 17 (54.8%) yielded 
ampliﬁ cation of the mini-exon PCR target, thereby allowing for PCR-RFLP-based identiﬁ cation. Six of the samples were 
identiﬁ ed as L. (V.) braziliensis, while the remaining 11 were identiﬁ ed as L. (V.) guyanensis. Conclusions: The results of 
this study demonstrate the feasibility of applying molecular techniques for the diagnosis of human parasites within parafﬁ n-
embedded tissues. Moreover, our ﬁ ndings conﬁ rm that L. (V.) guyanensis is a relevant causative agent of mucosal leishmaniasis 
in the Brazilian Amazon.
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Leishmaniasis remains a signiﬁ cant public health problem, 
occurring in 88 countries around the world. Each year, 
approximately 0.7-1.2 million people worldwide are affected 
by tegumentary leishmaniasis, with roughly 187,200-307,800 of 
these cases occurring on the American continent(1). Notably, of 
the 11 Leishmania species known to cause human disease, seven 
can be found in the Brazilian Amazon(2) (3) (4) (5). While the primary 
etiological agent of mucosal leishmaniasis (ML) in Brazil is 
Leishmania (Viannia) braziliensis, Leishmania (Leishmania) 
amazonensis and Leishmania (Viannia) guyanensis are also 
associated with mucosal lesions in this country(6).
In a previous study, Marsden(7), in 1986, estimated that 
3-5% of patients with cutaneous leishmaniasis subsequently 
develop the mucosal form of the disease(7). Because parasites 
are not easily detected in the lesions of patients with ML, the 
sensitivity of conventional diagnostic methods ranges between 
10 and 45%, rarely surpassing 50%(7). As such, diagnosis of 
ML is often based on clinical data associated with a positive 
result in the leishmanin skin test(8). In a recent meta-analysis, 
however, Gomes et al.(9) demonstrated that a polymerase 
chain reaction (PCR)-based method exhibited a sensitivity of 
71% for diagnosis of ML at the genus level(9). In addition, the 
sensitivity of non-invasive approaches has been studied with 
some interesting results(10). PCR is a sensitive method that can 
be used for the detection and characterization of Leishmania 
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species(11) (12). Indeed, several reports have considered this 
approach the method of choice for diagnosing ML(5) (13). Since 
Laskay(14) published his study(14), PCR has been utilized for the 
identiﬁ cation of Leishmania spp. in both parafﬁ n-embedded 
and nonembedded tissues, emphasizing the signiﬁ cance of 
this technique amongst available tools for the diagnosis of 
tegumentary leishmaniasis(15). Diagnosis of the causative agent 
of ML at the species level is essential, not only for assessing 
clinical prognoses, but also for the selection of appropriate 
treatments(16) (17).
In certain instances, patients with leishmaniasis are 
improperly diagnosed and treated at centers that are inexperienced 
with Leishmania infections, and it is only after the failure of 
these treatments that the patients are suspected of having ML. 
In such cases, the ability to examine parafﬁ n-embedded tissues 
for the presence of Leishmania spp. could be extremely useful 
to avoid the repetition of invasive procedures. The combination 
of conventional PCR coupled with restriction fragment length 
polymorphism (RFLP) may comprise a more practical approach 
for diagnosing parasites at the species level than the laborious 
process of multi-locus enzyme electrophoresis, which depends 
on the successful isolation of the parasite in culture, an event 
that is rare in ML patients. Moreover, a method that allows for 
species-level identiﬁ cation could enhance our knowledge of the 
parasitic diversity associated with this complex disease, which 
has traditionally been linked only to L. (V.) braziliensis infection.
The purpose of this study was to detect Leishmania 
deoxyribonucleic acid (DNA) in parafﬁ n-embedded biopsies 
of mucosal tissue harvested from the upper airways of patients 
that were followed-up at a reference center for the treatment of 
leishmaniasis in the Brazilian Amazon. Furthermore, we aimed at 
achieving species-level identiﬁ cation of the parasite(s) associated 
with mucosal impairment via PCR coupled with RFLP.
Sampling
This study was conducted at the Fundação de Medicina 
Tropical–Heitor Vieira Dourado (FMT-HVD), in Manaus, State 
of Amazonas, Brazil. Since 1990, FMT-HVD has functioned 
as a tertiary health unit that assists patients bearing lesions 
suspected to result from leishmaniasis. For such patients, routine 
procedures include histopathological examination of biopsies 
collected from upper airway tissues, which are ﬁ xed in 10% 
buffered formaldehyde, and subsequently embedded in parafﬁ n 
and archived in the Pathology Unit of FMT-HVD.
Sampling was defined by convenience and included 
biopsies of the upper airway mucosa of patients presenting 
lesions suspected to be ML. All biopsies were subjected to 
histopathological analysis between 1992 and 2008. Samples 
were identiﬁ ed from the pathology service logbook, which 
contains a record of the dates of clinical procedures and the 
results of histopathological examinations. The 114 biopsy tissues 
examined in this study were chosen based on the presence of 
at least nonspeciﬁ c inﬂ ammatory inﬁ ltrates, independent of 
the presence of Leishmania amastigotes, as determined by 
histopathological examination. In contrast, inclusion in the study 
was not dependent on parameters such as the extent of disease 
progression, previous exposure to treatment, or patient gender 
and age. Of the 114 samples analyzed, 91 were obtained from 
male patients, and 23 were obtained from female patients. A total 
of 59 samples were collected between 1992 and 2000, while the 
remaining 55 samples were collected between 2001 and 2008.
Histopathology
For histopathological diagnosis, hematoxylin and eosin 
(HE)-stained slides were examined by light microscopy to 
detect inﬂ ammatory inﬁ ltrates and/or the amastigote form of 
the parasite.
Deﬁ nition of cases of suspected 
mucosal leishmaniasis 
Cases of suspected mucosal leishmaniasis were clinically 
deﬁ ned by the presence of damage to the mucosal lining of 
the upper airway resulting in ulcers, in vegetative or necrotic 
lesions of the cartilaginous septum (with or without perforation), 
nasal turbinate, soft and hard palate, uvula, pharynx, or larynx, 
or deforming of the nasal pyramid(7). The team that conducted 
the present study was comprised of researchers that have been 
employed at FMT-HVD since at least 1990, and have experience 
with both ML and the use of the above-mentioned parameters 
for evaluating biopsies of the upper airway mucosa. Patients’ 
data, including the date of biopsy collection, age, gender, 
and the presence/absence of parasites upon conventional 
histopathological examination, were obtained retrospectively 
from medical records maintained by the institution. 
DNA extraction from tissues 
embedded in parafﬁ n
Twelve 20-µm sections were obtained from each block 
of parafﬁ n-embedded tissue and stored in 1.5mL microtubes 
at room temperature until further use. Paraffin removal 
was performed by incubation with xylol for 5 min at room 
temperature, followed by centrifugation at 14,000rpm for 
5 min at room temperature. The resulting pellet were washed 
twice with absolute ethanol, collected by centrifugation at 
14,000rpm for 5 min at room temperature, and air dried for 30 
min at 37ºC. DNA was then extracted using a DNeasy Blood 
& Tissue Kit (Qiagen®, Venlo, Netherlands), according to the 
manufacturer’s instructions. 
PCR ampliﬁ cation of the Leishmania 
kDNA target sequence
To detect Leishmania spp., PCR was utilized to amplify 
a 116 base pair (bp) constant region from the kinetoplast 
deoxyribonucleic acid (kDNA) mini-circle (henceforward 
referred to as PCR 13a/13b), as described previously(18). DNA 
harvested from cultures of L. (V.) guyanensis (MHOM/BR/1975/
M4147) and L. (V.) braziliensis (MHOM/BR/1975/M2903) were 
used as positive controls. To rule out false-negatives resulting 
from DNA degradation or to the presence of inhibitors, samples 
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subjected to a second PCR reaction using primers designed 
to target a speciﬁ c 147bp region of the human actin gene 
(ACTB ENSG00000075624, Ensemble).
PCR-RFLP of the mini-exon gene
For identiﬁ cation of parasite species, DNA samples that 
were positive for the PCR 13a/13b fragment were subjected to 
a second PCR analysis accompanied by enzymatic digestion. 
Ampliﬁ cation reactions were conducted using the following 
oligonucleotide primers, as described by Marfurt et al.(19): Fme 
(5´-TAT TGG TAT GCG AAA CTT CCG-3´) and Rme (5´-ACA 
GAA ACT GAT ACT TAT ATA GCG-3´). The Leishmania spp. 
present in each sample were subsequently identiﬁ ed by analyzing 
the fragments generated via restriction enzyme digestion with 
HaeIII and NcoI for 2.5h at 37ºC. Speciﬁ cally, while HaeIII 
cleaves the product ampliﬁ ed from L. (V.) braziliensis into 
118 and 108bp fragments, NcoI cleaves the L. (V.) guyanensis 
ampliﬁ cation product into 173 and 53bp fragments(19). Digestion 
products were separated by 3% agarose gel electrophoresis and 
visualized by ethidium bromide staining. 
Ethical considerations
The present study was conducted following the principles of 
the Helsinki Declaration and the resolution of National Health 
Council, which regulates research that involves humans in 
Brazil. This study has been approved by the FMT-HVD Ethics 
in Research Committee (protocol number 1674/06).
Direct examination detected parasites in 10 of the 114 (8.8%) 
samples tested, while histopathological examination detected 
amastigotes in an additional 17 (17/114; 14.9%) samples. 
Furthermore, 31 (31/114; 27.2%) samples were positive for 
the Leishmania spp. kDNA target (PCR 13a/13b) as shown in 
Figure 1. Of these, only 17 (54.8%) yielded ampliﬁ cation of 
the mini-exon PCR product and could therefore be analyzed 
by PCR-RFLP. While 6 of the samples were identiﬁ ed as 
L. (V.) braziliensis, the other 11 were conﬁ rmed as L. (V.) 
guyanensis. Notably, only partial digestion of the DNA product 
resulting from the PCR mini-exon assay was observed using 
the conventional protocol. As a result, it was necessary to 
increase the digestion time to 3h to achieve optimal digestion 
(Figure 2). Lastly, the human actin gene was successfully ampliﬁ ed 
in each of the 83 samples that were PCR 13a/13b-negative.
M            1           2            3           4           5
116 pb
M            C+       C+         C+         C-
116 pb
FIGURE 1 - Electrophoretic analysis of PCR 13a/13b fragments. 
Samples were separated by 2% agarose gel electrophoresis. Five 
samples were positive for Leishmania spp. [116 base pair (bp 
amplicon]. Lanes 1, 2, 3, 4 and 5: M: 100bp molecular marker; 
C+: positive control; C-: negative control; The positive controls 
were as follows: Leishmania (Viannia) braziliensis (MHOM/
BR/1975/M2903), Leishmania (Viannia) guyanensis (MHOM/
BR/1975/M4147), and Leishmania (Leishmania) amazonensis 
(IFLA/BR/1967/PH8). PCR: polymerase chain reaction.






FIGURE 2 - Enzymatic digestion analysis of DNA products 
generated by mini-exon PCR. PCR products were restriction 
digested with HaeIII and NcoI, and separated by 3% agarose 
gel electrophoresis. Lanes 1, 2, 3, and 5 correspond to patient 
DNA samples digested with HaeIII, while lanes 7, 8, 9, and 11 
contain patient DNA samples digested with NcoI. Lanes 4 and 
10 contain the positive control [Leishmania (Viannia) guyanensis 
(MHOM/BR/1975/M4147)] DNA digested with HaeIII and NcoI, 
respectively. Lane 6 contains the 100 base pair (bp) DNA ladder. 
DNA: deoxyribonucleic acid; PCR: polymerase chain reaction.
Given their dependence on parasite visualization within 
affected tissues or on parasite isolation in culture, the use 
of conventional tools to diagnose Leishmania spp. as the 
causative agent of damage to the upper airway mucosa remains 
a major challenge(7) (20). Moreover, because these techniques 
are associated with low levels of accuracy, the development 
of methods, such as PCR-based diagnostic methods, that yield 
higher levels of sensitivity and speciﬁ city is necessary(13) (21). 
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In this study, we successfully detected genus-speciﬁ c DNA 
fragments in a large number of mucosal samples collected 
from the upper airway of Brazilian patients suspected of 
leishmaniasis. Notably, our results indicate that the methodology 
utilized in this study would have provided conﬁ rmatory results 
for a third of these suspected ML patients. 
Given the lack of speciﬁ city of the clinical parameters used 
for inclusion in this study, we expected that the majority of the 
patients evaluated would by negative for parasites upon PCR 
analysis. Unfortunately, due to a lack of systematic collection 
of additional relevant data during the period in which these 
patients were being treated, it was not possible to determine 
a deﬁ nitive diagnosis for those patients that tested negative 
for Leishmania spp. Nevertheless, our study demonstrates the 
need for further exploration of the role of L. (V.) guyanensis 
in ML etiology, a disease that has traditionally been linked to 
L. (V.) braziliensis infection(7). Indeed, there is a scarcity of 
information regarding the role of L. (V.) guyanensis in ML. 
While a previous study performed at FMT-HVD in the 1990s 
demonstrated the predominance of L. (V.) guyanensis among 
cases of cutaneous leishmaniasis(22), the relative frequency of the 
mucosal impairment caused by this species remains unknown. 
Furthermore, consistent with recent ﬁ ndings in Brazil(5), cases 
of ML caused by L. (V.) guyanensis and L.(V.) panamensis were 
recently described in Colombia(23) (24). In the present study, PCR-
RFLP analysis detected a higher number of cases of infection 
by L. (V.) guyanensis than by L. (V.) braziliensis. However, this 
result should be assessed with caution, as skin ulcers caused by 
L.(V.) guyanensis appear to be associated with higher parasite 
burdens than ulcers caused by L.(V.) braziliensis(17). Regardless, 
these ﬁ ndings highlight the feasibility of using molecular 
techniques both for analyzing parafﬁ n-conserved biological 
material and for diagnosing ML. Furthermore, they demonstrate 
that PCR-RFLP comprises a method that can be utilized to 
achieve species-speciﬁ c diagnoses. The efﬁ cacy of methods 
for the extraction of optimal concentrations of DNA with high 
levels of purity and integrity from parafﬁ n-embedded tissues 
is essential for the molecular diagnostic approach utilized in 
this study. Nonetheless, the processes of formaldehyde ﬁ xation 
and inclusion into parafﬁ n are limiting steps for the molecular 
detection of parasites(14) (15) (25) (26). 
In the present study, human DNA was amplified from 
all biopsy-extracted DNA samples. However, the relative 
abundance of this target, which was used as control for DNA 
extraction, does not necessarily mean that the parasite DNA was 
not degraded during ﬁ xation and conservation(27). The length of 
time during which samples are maintained in parafﬁ n blocks is 
an important factor for DNA ampliﬁ cation, as previous research 
indicates that there is a negative correlation between the duration 
of storage and PCR success(25). In the present study, while 
storage duration was not a limiting factor for the ampliﬁ cation 
of the human actin gene, it could have had deleterious effects 
on the detection of Leishmania spp. and on the identiﬁ cation 
of parasite species. Indeed, when compared to samples that had 
been stored for shorter periods, a small number of the older 
samples were positive in the PCR assay and yielded faint bands 
upon electrophoretic analysis. 
The low percentage of Leishmania-positive samples in this 
study might have been due, at least in part, to degradation of the 
parasite DNA, as ﬁ xation promotes folding of nuclear proteins 
and the degradation of DNA molecules(28). In addition, parasite 
numbers within mucosal lesions are often low(29). Given that 
the efﬁ ciency of DNA ampliﬁ cation decreases as the target 
DNA fragment size increases, targeting of the PCR 13a/13b 
fragment, which is both abundant(30) and small, may provide a 
plausible explanation for the positive results achieved with this 
test, compared to that of mini-exon PCR-RFLP analysis(26) (31). In 
summary, the present study demonstrates the efﬁ cacy of molecular 
techniques for diagnosis of ML using parafﬁ n-embedded tissues. 
Our data also conﬁ rm that L. (V.) guyanensis comprises a relevant 
etiological agent of ML in the Brazilian Amazon.
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